In its notice of decision
dated March 16, 2018, Health Canada declared that «changes made in this
rice variety did not pose a greater risk to human health than
rice varieties currently available on the Canadian market», further noting that «GR2E would have no impact on allergies, and that there were no differences in the nutritional value of GR2E compared to other traditional
rice varieties available for
consumption except for increased levels of provitamin A.
Last year, the FDA released what we believe to be the largest set of test results to
date on the presence of arsenic in
rice and
rice products, and we are planning to release a draft assessment of the potential health risks associated with the
consumption of arsenic in these same foods.»